The majority (49.0%) of chronic kidney disease patients had second-stage primary arterial hypertension (Table 1) and were discharged on angiotensin-converting enzyme inhibitors (65.2%), calcium channel blockers (49.7%), and the diuretic, antihypertensive drug class (47.7%). The gene discussed is ACE; the disease is chronic kidney disease.